Non-Muscle Invasive Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Monika Joshi, MD, MRCPAdvanced Urothelial Carcinoma | April 17, 2024
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
View More
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 16, 2024
Ferring Pharmaceuticals has expanded their Adstiladrin clinical trial program to include 3 new studies in NMIBC.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 15, 2024
The FDA has accepted the Investigational New Drug Application for UGN-103 for low-grade intermediate-risk NMIBC.
Amanda Myers, MDNon-Muscle Invasive Urothelial Carcinoma | April 9, 2024
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Zachary BessetteNon-Muscle Invasive Urothelial Carcinoma | April 8, 2024
Some patients who meet the FDA criteria for “BCG-unresponsive” bladder cancer may benefit from additional BCG therapy.
James “Jed” Ferguson III, MD, PhDNon-Muscle Invasive Urothelial Carcinoma | March 29, 2024
Dr. Ferguson highlights the latest TAR-210 and TAR-200 data in select patients with non-muscle invasive bladder cancer.
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | March 11, 2024
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | February 8, 2024
The guidelines included recommendations for treatment with TURBT and postoperative intravesical chemotherapy.
Sia Daneshmand, MDASCO GU Symposium 2024 | February 6, 2024
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
Katy MarshallNon-Muscle Invasive Urothelial Carcinoma | February 1, 2024
The trial indicated a "favorable risk/benefit ratio and quality of life" associated with the treatment.
Zachary BessetteASCO GU Symposium 2024 | March 11, 2024
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Melissa BadamoUrothelial Carcinoma | January 24, 2024
Nadofaragene firadenovec-vncg is now fully available for health care providers to prescribe across the US for NMIBC.
David Ambinder, MDUrothelial Carcinoma | January 16, 2024
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
Seth Lerner, MD, FACSNon-Muscle Invasive Urothelial Carcinoma | December 18, 2023
Dr. Lerner shares his thoughts on the results of ENVISION and the potential for UGN-102 for lg/ir NMIBC.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel conclude with their thoughts on considerations for TURBT and intravesical therapy versus chemoablation.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel considers therapies across different risk stratifications, including ATLAS, ENVISION, and BOND-003 studies.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel delves into treatment pathways, including considerations for ablation and repeated histologic evaluation.
Christopher Wallis, MD, PhD, FRCSCRoundtable | December 8, 2023
The panel kicked off with conversations about risk stratification and classification of low-grade, intermediate-risk disease.
Christopher Wallis, MD, PhD, FRCSCSUO 2023 | November 30, 2023
Dr. Prasad presented the results of the ENVISION trial assessing primary chemoablation in patients with LG-IR NMIBC.
Emily MenendezSUO 2023 | January 3, 2024
An in vitro model of EV-resistant bladder cancer showed that EV resistance was mainly due to resistance of the payload MMAE.
Advertisement
Advertisement
Advertisement